Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 6/20 | 0.33 |
| ▸ | FPR1 | P21462 | 5/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11976288 | 1.00 | CTSB (0.39) | CTSBCTSSBDKRB1FPR2FPR1 | |
| SCHEMBL3793073 | 1.00 | CTSB (0.39) | CTSBCTSSBDKRB1FPR2FPR1 | |
| SCHEMBL1683141 | 1.00 | CTSB (0.39) | CTSBCTSSBDKRB1FPR2FPR1 | |
| SCHEMBL13082876 | 0.93 | CTSB (0.38) | CTSBCTSSF2CRBN | |
| SCHEMBL11976287 | 0.92 | CTSB (0.42) | CTSBCTSSMEN1F2 | |
| SCHEMBL3797097 | 0.92 | CTSB (0.42) | CTSBCTSSMEN1F2 | |
| SCHEMBL13082477 | 0.92 | CTSB (0.39) | CTSBCTSSF2CRBN | |
| SCHEMBL1646382 | 0.92 | CTSB (0.42) | CTSBCTSSMEN1F2 | |
| SCHEMBL12808436 | 0.92 | CTSB (0.40) | CTSBCTSSBDKRB1KMT2AMEN1 | |
| SCHEMBL13059615 | 0.92 | CTSB (0.40) | CTSBCTSSBDKRB1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305697-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305695-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305698-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305696-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090148407-A1 | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication | EIF2AK2, HAVCR2, HCCS | CTSB 541/4885CTSS 837/4885BDKRB1 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.